Skip to main content
Infection & Chemotherapy logoLink to Infection & Chemotherapy
. 2022 Apr 28;54(2):391. doi: 10.3947/ic.2022.0300

Erratum: Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial

PMCID: PMC9259899  PMID: 35706085

We found error in our published article.

Materials and methods

Before: 3. Participants

“Patients who had symptoms consistent with COVID-19 with onset less than 7 days after randomization and had positive RT-PCR results within 3 days of randomization were enrolled (Figure 1).”

After: 3. Participants

“Patients who had symptoms consistent with COVID-19 with onset less than 7 days and positive RT-PCR results within 3 days before randomization were enrolled (Figure 1).”

Figure 1

Before: 97 excluded

14 symptom onset>3 days ago

After: 97 excluded

14 symptom onset>7 days ago

We apologize for any inconvenience that it may have caused.


Articles from Infection & Chemotherapy are provided here courtesy of Korean Society of Infectious Diseases

RESOURCES